Mucinous metaplasia in Pten conditional knockout mice and mucin family genes as prognostic markers for prostate cancer.
Mucinous metaplasia
Prognostic marker
Prostate cancer
Transcriptome
androgen receptor
lineage plasticity
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
15 Mar 2022
15 Mar 2022
Historique:
received:
26
10
2021
revised:
11
12
2021
accepted:
19
12
2021
pubmed:
16
1
2022
medline:
22
2
2022
entrez:
15
1
2022
Statut:
ppublish
Résumé
This study evaluated the association of mucinous metaplasia (MM) with tumor cell proliferation, androgen receptor (AR) expression and invasiveness in Pten conditional knockout mice and the prognostic value of MM markers for patients with PCa. Prostatic lobes samples from genetic engineered mouse model Pten All knockout animals analyzed showed at least one area of stroma-invading MM, which was absent in the control animals. The tumoral regions of MM showed a proliferative index 5 times higher than other tumoral areas and low expression of the AR (less than 20% of the cells were AR-positive). Disrupted basement membrane areas were observed in MM. The mouse and human PCa transcriptomes exhibited increased expression of the MM markers such as MUC1, MUC19, MUC4, MUC5AC, MUC5B, and TFF3. Gene expression profile was associated with castration-resistant prostate cancer (CRPC) and with a lower probability of freedom from biochemical recurrence. The expression of goblet cell genes, such as MUC1, MUC5AC, MUC5B, and TFF3 have significant prognostic value for PCa patients and represent another class of potential therapeutic targets.
Identifiants
pubmed: 35031262
pii: S0024-3205(21)01251-0
doi: 10.1016/j.lfs.2021.120264
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Mucins
0
PTEN Phosphohydrolase
EC 3.1.3.67
Pten protein, mouse
EC 3.1.3.67
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
120264Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.